Introduction

In part 1 of our review on somatostatin (SST) receptor biology in neuroendocrine tumours, the somatostatin receptor (SSTR) as a G-protein coupled receptor (GPCR), and the anti-tumour effects of SST and SSTR post-signalling pathways, were reviewed. To recapitulate, SST is a peptide hormone which acts mainly as an inhibitor in many endocrine systems. SST has five receptor subtypes (SSTR1-5) with SSTR2 as the most commonly expressed form in both normal and tumoral tissues. SST has been widely investigated for its anti-tumoral effects and their mechanisms, and currently there are two SST analogues (lanreotide and octreotide) in clinical use. The anti-proliferative action of SST mainly occurs through phosphotyrosine phosphatases which modulate MAPK and PI3K/Akt pathways. On the other hand, its anti-secretory action occurs through decreased intracellular cAMP, K
. Specifically, at both mRNA and protein levels SSTR2, SSTR5 and D2 coexpression has been found in most GH-secreting adenomas [11] . However, some 50% GH-secreting tumours, particularly mixed GH/PRL adenomas, also coexpress SSTR3 and SSTR1 [10, [12] [13] [14] [15] [16] . The expression of SSTR2 was found to be positively correlated with the in vivo GH suppression induced by octreotide [17, 18] . Conversely, in a study by Plöckinger [11] . On the other hand, in some cell culture studies SSTR5 selective SST analogues were found to be more potent [20] . Moreover, the combined activation of SSTR2 and SSTR5 results in additive inhibitory effects on GH secretion which has led to the synthesis of new bi-selective agonist compounds that bind to both SSTR2 and SSTR5 [21] .
The majority of prolactinomas express high numbers of D2R and SSTR1. SSTR5 is also notably present, while SSTR2 is only expressed in a minority of them [10, 12, [22] [23] [24] [11, 31, 32] . In a recent study, pasireotide was shown to be less potent than octreotide in inducing internalization and the signalling of SSTR2 receptors expressed in HEK cells [33] . In contrast, pasireotide was more potent than octreotide in inducing internalization and signalling of SSTR3 and SSTR5 receptors [33] . In a study by Pöll and colleagues, SST and octreotide was shown to stimulate rapid cointernalization of the rat SSTR2A and ss-arrestin into the same endocytic vesicles [34] . In contrast, pasireotide failed to promote substantial phosphorylation and internalization of the rat SSTR2A. Additionally, in the presence of octreotide or SST, pasireotide showed partial agonist behaviour, inhibiting phosphorylation, and internalization of SSTR2A [34] . Pasireotide-mediated phosphorylation led to the formation of relatively unstable ␤-arrestin-SSTR2A complexes that dissociated at or near the plasma membrane. Thus, octreotide and pasireotide were found to be equally active in inducing classical G protein-dependent signalling via the SSTR2A, yet they promoted strikingly different patterns of SSTR2A phosphorylation [34] . In the first, uncontrolled phase II trial in human, pasireotide caused a reduction in urinary free cortisol levels in 76% of patients with Cushing's disease during a treatment period of 15 days, with direct effects on ACTH release, while normalization of urinary free cortisol occurred only in 17% of patients [35] . As it potently suppresses GH and IGF-I secretion and, furthermore multiple SSTR expression is a feature of carcinoid tumours, pasireotide may have potential efficacy in acromegaly and the carcinoid syndrome as well [36] . [10, 12, 16, 37] . In patients treated with octreotide, TSH level normalization was noted in 80%, whereas significant tumour shrinkage was observed in 50% [11] . Beck-Peccoz and colleagues have reported even better results with more than 90% of patients achieving normalization of free T4 and free T3 [38] [39] [40] . In a recent study it was demonstrated that SSTR2 is the SSTR subtype predominantly expressed in a series of TSH-secreting adenomas [41] [16] . These drugs may be favourable in acromegaly and other pituitary tumours and also gastrointestinal endocrine tumours where tachyphylaxis may limit SST analogue efficacy [16] .
Thyroid-stimulating hormone (TSH)-secreting tumours, although very rare, significantly express SSTR1, SSTR2 and SSTR5
When it comes to GEP-NETS, these tumours may be 'functioning' and thus cause a clinical syndrome due to hormonal hypersecretion, or 'non-functioning' when the symptoms are related only to the mass effect of the tumour [11] . Regarding SSTR expression, it has been reported that in the endocrine pancreas SSTR5 and at lower levels SSTR1 are expressed in insulin secreting ␤-cells, SSTR2 is mainly expressed in glucagon-secreting ␣-cells and SSTR5 in the SST-releasing ␦-cells, while SSTR3 and SSTR4 are poorly expressed [42, 43] [48] .
In a study testing the cytotoxicity of novel SST and dopamine chimeric compounds in bronchopulmonary and small intestinal neuroendocrine tumour cell lines, it was revealed that the drug response was very heterogeneous among different tissues, and it was concluded that NETs from different locations arising from different neuroendocrine cells may require cell-specific anti-proliferative agents based on the unique receptor profile of individual lesions
GEP-NETs usually express a high density of SSTRs (this can be expressed as pmol receptors/g tissue), and in SSTR2
ϩ and SSTR5 ϩ tumours symptoms related to hormone hypersecretion can be controlled by the administration of SST analogues in around 90% of patients [11] . [50] . Those [51] . In this study by Rinke and [52] . Future studies will show whether this analogue also has better anti-proliferative effect, as indicated on phaeochromocytoma cells (see below) [53, 54] Another diagnostic and therapeutic application is imaging of NETs with labelled SST analogues followed by radionuclide therapy. Peptide receptor imaging (PRI) and radionuclide therapy (PRRT) can be combined in a single probe which has been named as 'theranostic' by some authors [56] . The idea that lies behind this approach is the exploitation of the specific receptor binding properties of the peptide ligand by using a radiolabelled ligand to guide the radioactivity to the tumours expressing a particular receptor [56] . [56] . In addition, peptides labelled with ␤-particle emitters (yttrium-90 and lutetium-177) have the potential to eradicate receptorexpressing tissues: this approach is referred to as PRRT [56] [64] .
SST analogue treatment has been recently recommended in functioning NETs in European Neuroendocrine Tumour Society Guidelines [49]. Although tumour shrinkage has also been observed in a small number of patients, SST analogue therapy does not offer a curative treatment regimen and the tumour advances in nearly all patients with GEP-NETS [11]. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SST analogues in selected patients
patients with a progressive, non-functional GEP-NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SST analogues. The exploration of the mechanisms of this effect is unclear and hampered by the lack of suitable preclinical models. Very recently, for the first time the clear anti-proliferative effects of octreotide in well-differentiated metastatic midgut NETs have been shown in a placebo-controlled, double-blind, phase IIIB study
The high affinity of the ligand for the receptor facilitates retention of the radiolabel in the tumour. Receptor-binding peptides labelled with ␥-radiation emitters for SPECT (indium-111 and technetium-99m) or positron emitters for PET (gallium-68 and fluorine-18) enable visualization of receptor-expressing tissues non-invasively: a technique referred to as PRI
In patients with medullary thyroid carcinoma both SST analogues and tumour-targeted radioactive treatment using radiolabelled SST analogues have limited therapeutic value due to minor radioactivity uptake by these tumours in most patients [65] . In pituitary tumours from different origins, 111 In-pentetreotide scintigraphy is also of very low value.
Conclusions
The [68] . In contrast, due to its rapid down-regulation, the SSTR3 receptor appears to be a less favourable pharmacological target [68] .
It seems that SST analogues will be a cornerstone treatment for NETs in the foreseeable future. Several analogues and chimeric molecules with different signalling properties are being developed, and many are on their way. Better understanding of the effects of these agents and modulated pathways will clarify the putative role SST analogues in the treatment of not only NETs but also in other cancers that are also well known to express SSTRs.
